Abstract
The present study assessed the magnitude of inhibition of platelet aggregation induced by adenosine diphosphate and thrombin receptor activating peptide achieved with unfractionated heparin, the direct thrombin inhibitor bivalirudin, and the glycoprotein IIb/IIIa inhibitor eptifibatide in patients who underwent percutaneous coronary intervention and and were treated with concomitant aspirin and clopidogrel.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
MeSH terms
-
Angioplasty, Balloon, Coronary*
-
Anticoagulants / pharmacokinetics
-
Anticoagulants / therapeutic use
-
Clopidogrel
-
Drug Therapy, Combination
-
Eptifibatide
-
Female
-
Follow-Up Studies
-
Heparin / therapeutic use*
-
Hirudins / pharmacokinetics*
-
Humans
-
Male
-
Middle Aged
-
Myocardial Ischemia / blood
-
Myocardial Ischemia / therapy*
-
Peptide Fragments / pharmacokinetics*
-
Peptide Fragments / therapeutic use
-
Peptides / pharmacokinetics*
-
Peptides / therapeutic use
-
Platelet Aggregation / drug effects*
-
Platelet Aggregation Inhibitors / pharmacokinetics
-
Platelet Aggregation Inhibitors / therapeutic use
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Preoperative Care / methods
-
Recombinant Proteins / pharmacokinetics
-
Recombinant Proteins / therapeutic use
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / pharmacokinetics
-
Ticlopidine / therapeutic use
-
Treatment Outcome
Substances
-
Anticoagulants
-
Hirudins
-
Peptide Fragments
-
Peptides
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Recombinant Proteins
-
Heparin
-
Clopidogrel
-
Eptifibatide
-
Ticlopidine
-
bivalirudin